News

2 January 2009

 

Cree elects GlaxoSmithKline’s Ingram to board

LED maker Cree Inc of Durham, NC, USA says that Robert Ingram, vice chairman Pharmaceuticals of GlaxoSmithKline, has been elected to its board of directors, and to the board’s Compensation Committee and Governance and Nominations Committee.

Ingram has served since January 2003 as vice chairman Pharmaceuticals of GlaxoSmithKline, a pharmaceutical R&D firm in Research Triangle Park, NC. He was previously chief operating officer and president of Pharmaceutical Operations of GlaxoSmithKline following the December 2000 merger of Glaxo Wellcome plc and SmithKline Beecham plc. Prior to the merger, he was CEO of Glaxo Wellcome plc and chairman, president & CEO of Glaxo Wellcome Inc.

Picture: Robert Ingram.

Ingram also serves on the boards of directors of Lowe's Companies Inc, Allergan Inc, and Edwards Lifesciences Corp, as chairman of the board of directors of OSI Pharmaceuticals Inc, and as lead director of Valeant Pharmaceuticals International.

“His wealth of experience in research-intensive businesses facing global marketing and manufacturing challenges give him an ideal foundation to help us address the opportunities Cree anticipates,” says chairman & CEO Chuck Swoboda. “The insights he brings should prove beneficial to Cree as we work toward our goal of replacing traditional lighting solutions with energy-efficient, environmentally friendly LED lighting.”

See related item:

Cree grows 24% year-on-year to record $140m revenue

Search: Cree LEDs

Visit: www.cree.com